USPTO serial 79324555
B
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 1, 2022
- Examiner
- BLOHM, LINDA
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with B?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Chengdu Brilliant Pharmaceutical Co., Ltd.
CN
Other trademarks owned by Chengdu Brilliant Pharmaceutical Co., Ltd.
Chengdu Brilliant Pharmaceutical Co., Ltd.
CN
Other trademarks owned by Chengdu Brilliant Pharmaceutical Co., Ltd.
Chengdu Brilliant Pharmaceutical Co., Ltd.
CN
Other trademarks owned by Chengdu Brilliant Pharmaceutical Co., Ltd.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Paulo A. de Almeida
Paulo A. de Almeida Patel & Almeida, P.C.16830 Ventura Blvd., Suite 360Encino, CA 91436UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Cultures of microorganisms for medical or veterinary use; medical dressings; pharmaceutical preparations for human use for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations for human use for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; pharmaceutical preparations for human use for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; pharmaceutical preparations for human use, namely, anti-infectives; antifungal pharmaceutical preparations for human use; Chinese traditional medicinal herbs for human use; pharmaceutical preparations for human use for antitussive-cold; pharmaceutical preparations for human use for the prevention and treatment of cancer; pharmaceutical preparations for human use for the treatment of psychiatric diseases and disorders; pharmaceutical preparations for human use for the treatment of heart rhythm disorders; medicated throat sprays for human use; diuretic pharmaceutical preparations for human use; pharmaceutical preparations for human use for the treatment of musculo-skeletal disorders; pharmaceutical preparations for human use for the treatment of hyperlipidemia; antitussives for human use; otorhinolaryngological pharmaceutical preparations for human use; anaesthetics for human use; pharmaceutical preparations for human, namely, antidepressants; pharmaceutical preparations for human use for the treatment of eye diseases and conditions; headache treatment pharmaceutical preparations for human use; nasal spray preparations for human use; medicines for human use for the treatment of gastrointestinal diseases; medicinal preparations for the mouth and as sprays for human use; thyroid and para-thyroid hormone pharmaceutical preparations for human use; sulfonamide pharmaceutical preparations for human use; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension for human use; pharmaceutical preparations acting on the central nervous system for human use; pharmaceutical preparations for human use for the treatment of erectile dysfunction; pharmaceutical solutions used in dialysis for human use; pharmaceutical preparations for human use for the treatment of bone diseases; antipyretic analgesics for human use; antiallergic medicines for human use; anti-diabetic pharmaceutical preparations for human use; hypnotic sedatives for human use; cardiovascular pharmaceutical preparations for medical purposes for human use; hemostatics for medical purposes for human use; antihemorrhoidal pharmaceutical preparations for human use; anti-epileptic pharmaceutical preparations for human use; cerebral hemorrhage prophylactic pharmaceutical preparations for human use; pharmaceutical preparations for human use for the treatment of immune system related diseases and disorders; pharmaceutical preparations for human use for treating hypertension; athlete's foot pharmaceutical preparations for human use; pharmaceutical preparations for human use for treating asthma; pharmaceutical preparations for human use for the treatment of hormonal disorders; medicated mouth treatment pharmaceutical preparations for human use; motion sickness medicines for human use; diarrhea medication for human use; pesticides; medicines for veterinary purposes, namely, pain relief medication; veterinary vaccines; anti-infectives products for veterinary use; bacteriological medicinal preparations for veterinary purposes; medicines for veterinary purposes, namely, for treatment of intestinal bacteria; medicines for veterinary purposes for the treatment of animals' skin diseases; medicines for veterinary purposes for the treatment of wounds; albumin dietary supplements for medical purposes; depuratives for the body; oxygen for medical purposes; nitrous oxide for medical use; radioactive substances for medical purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Chengdu Brilliant Pharmaceutical Co., Ltd.
- Other trademarks owned by Chengdu Brilliant Pharmaceutical Co., Ltd.
- Other trademarks owned by Chengdu Brilliant Pharmaceutical Co., Ltd.
- Other trademarks in Class 005
- Similar marks named B
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 21, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 28, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 27, 2023 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 1, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 1, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Nov 1, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 17, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 17, 2022 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Aug 16, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 16, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 27, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jul 27, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 27, 2022 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jul 11, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 8, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 7, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 7, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 4, 2022 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 14, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 14, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 12, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 11, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 4, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 12, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 8, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 5, 2021 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Oct 29, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |